Vimarsana
Biggest News Aggregation in the World

Page 23 - Looking Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Looking Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Looking Statement Today - Breaking & Trending Today

Evaxion Biotech Announces Closing of Private Placement - Vimarsana News

Evaxion Biotech Announces Closing of Private Placement

MSD Global Health Innovation Fund , a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, is contributing with some 25% of the total offering amount Company’s management and board...

Kingsman Resources Provides Las Coloradas Project Year-end Summary - Vimarsana News

Kingsman Resources Provides Las Coloradas Project Year-end Summary

Kingsmen Resources Ltd. is pleased to provide a year-end summary of its activities on the Las Coloradas project, located 30km from Hildago de Parral, Chihuahua, Mexico. Portions of the Soledad...

FDA Grants Priority Review to Merck's New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults -December 19, 2023 at 06:46 am EST - Vimarsana News

FDA Grants Priority Review to Merck's New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults -December 19, 2023 at 06:46 am EST

Acceptance based on results from multiple Phase 3 trials If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults The 21 serotypes covered by V116 are...

Evaxion Biotech Announces Private Placement Financing - Vimarsana News

Evaxion Biotech Announces Private Placement Financing

MSD Global Health Innovation Fund , a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, is contributing with some 25% of the total offering amount Company’s management and board...

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer -December 18, 2023 at 06:46 am EST - Vimarsana News

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer -December 18, 2023 at 06:46 am EST

KEYTRUDA now approved for 26 indications in the EU, including seven in gastrointestinal cancers ...